reboxetine has been researched along with Parkinson Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciucci, MR; Hoffmeister, JD; Kelm-Nelson, CA | 1 |
| Borghammer, P; Brooks, DJ; Damholdt, MF; Fedorova, TD; Hansen, A; Ismail, R; Kinnerup, MB; Knudsen, K; Nahimi, A; Pavese, N; Schaldemose, JL; Skjærbæk, C; Sommerauer, M; Stær, K; Terkelsen, AJ | 1 |
| Lemke, MR | 2 |
| Caraceni, T; Eichhorn, T; Girotti, F; Höglinger, GU; Krieg, JC; Oertel, WH; Poewe, W; Spottke, AE | 1 |
1 review(s) available for reboxetine and Parkinson Disease
| Article | Year |
|---|---|
Depression in Parkinson's disease. An update.
Topics: Adrenergic Uptake Inhibitors; Depression; Humans; Morpholines; Parkinson Disease; Reboxetine | 2001 |
1 trial(s) available for reboxetine and Parkinson Disease
| Article | Year |
|---|---|
Effect of reboxetine on depression in Parkinson's disease patients.
Topics: Adrenergic Uptake Inhibitors; Aged; Depressive Disorder; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Morpholines; Parkinson Disease; Personality Inventory; Psychiatric Status Rating Scales; Reboxetine; Severity of Illness Index; Treatment Outcome | 2002 |
3 other study(ies) available for reboxetine and Parkinson Disease
| Article | Year |
|---|---|
Manipulation of vocal communication and anxiety through pharmacologic modulation of norepinephrine in the Pink1-/- rat model of Parkinson disease.
Topics: Adrenergic Uptake Inhibitors; Animals; Anxiety; Atomoxetine Hydrochloride; Disease Models, Animal; Humans; Male; Norepinephrine; Parkinson Disease; Protein Kinases; Rats; Rats, Long-Evans; Reboxetine; Vocalization, Animal | 2022 |
Preserved noradrenergic function in Parkinson's disease patients with rest tremor.
Topics: Adrenergic Neurons; Aged; Brain; Carbon Radioisotopes; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Presynaptic Terminals; Radiopharmaceuticals; Reboxetine; Tremor | 2021 |
Reboxetine treatment of depression in Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Aged; Depressive Disorder; Drug Administration Schedule; Female; Humans; Morpholines; Norepinephrine; Parkinson Disease; Reboxetine; Treatment Outcome | 2000 |